Lung cancer

Adjuvant immunotherapy the new standard of care in patients with resected, early-stage NSCLC?

Patients with resected, early-stage non-small cell lung cancer (NSCLC) may benefit from adjuvant immunotherapy following adjuvant chemotherapy, according to new findings from a trial of atezolizumab. Presented at the European Society for Medical Oncology (ESMO) virtual Congress 2021, the results from the IMpower010 phase 3 RCT showed that  atezolizumab extended disease-free survival in patients with stage II–IIIA ...

Already a member?

Login to keep reading.

© 2021 the limbic